Onabotulinum Toxin A

ApprovedSmall molecule

WWalter Reed National Military Medical Center

Onabotulinum Toxin A is one of 156 small molecule programs targeting Neuropathic Pain. It is currently in Approved.

Indications

Total Trials

Active Trials

155

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neuropathic PainActive, not recruiting

Lung CancerActive, not recruiting

Interstitial CystitisActive, not recruiting

MigraineActive, not recruiting

WrinklesActive, not recruiting

Overactive BladderActive, not recruiting

Neuropathic PainPhase 2

Active, not recruiting

Lung CancerPhase 1/Phase 2

Active, not recruiting

Interstitial CystitisPhase 2

Active, not recruiting

MigraineApproved

Active, not recruiting

WrinklesPhase 1

Active, not recruiting

Overactive BladderPhase 2

Active, not recruiting

Competition

Competitive Landscape

686 competitors in Lung Cancer

#DrugCompanyPhaseTrials

Onabotulinum Toxin A

WWalter Reed National Military Medical Center

Approved

1 2

Tecentriq

Roche

Preclinical

9 3

Libtayo

Regeneron

Preclinical

3 4

Vizimpro

Pfizer

Preclinical

3 5

Talzenna

Pfizer

Preclinical

2 6

Folvite

Xylocaine

2 8

Immunotherapy

Bristol-Myers Squibb

Preclinical

5 9

Paclitaxel and Carboplatin

Bristol-Myers Squibb

Preclinical

2 10

Rilotumumab

Amgen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Recruiting

Conservative Management

NCT06729151

Q4 2027

Phase 1Active, not recruiting

Wrinkles

NCT02019004

Clinical

Trials by Indication[1]

Lung Cancer1 trial

Botulinum Toxin A as Treatment for Chronic Postsurgical Pain Following Lung Cancer Surgery

Unknown status·—·Phase 1/2·NCT04585620·30 enrolled

Facial Wrinkles1 trial

Efficacy of Prabotulinum and Onabotulinum Toxin-A for Facial Wrinkles

Completed·IInstituto de Oftalmología Fundación Conde de Valenciana·Phase 4·NCT05840445·26 enrolled

Botulinum Toxin1 trial

A Study Comparing the Safety, Efficacy, and Diffusion of Letibotulinum Toxin A Versus Other Botulinum Toxin Products in Adults With Moderate-to-Severe Forehead Wrinkles

Completed·YYonsei University·Phase 4·NCT07072806·20 enrolled

Overactive Bladder1 trial

Instillation of Botox in the Bladder in Women With Overactive Bladder (OAB)

Completed·—·Phase 2·NCT02735499·14 enrolled

Migraine1 trial

Sustained onabotulinumtoxinA Therapeutic Benefits in Patients With Chronic Migraine

Completed·CCorfu Headache Clinic·Phase 4·NCT03606356·56 enrolled

5 more indications

Neuropathic Pain1 trial

Intraoral Administration of Botox in Patients With Dentoalveolar Neuropathic Pain

Completed·IIsabel Moreno Hay·Phase 2·NCT03848143·10 enrolled

Interstitial Cystitis1 trial

Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome

Completed·WWalter Reed National Military Medical Center·Phase 2·NCT04401176·58 enrolled

Conservative Management1 trial

Effect of Intradetrusor onabotulinumtoxinA Injection Versus Conservative Management on Female Sexual Function in Patients With Bladder Pain Syndrome

Recruiting·WWalter Reed National Military Medical Center··NCT06729151·159 enrolled

Glabellar Lines1 trial

Split-Face Study Comparing Botox and Jeuveau in Treating Glabellar Lines

Unknown status·UUniversity of Southern California·Phase 1·NCT04715048·20 enrolled

Wrinkles1 trial

Treatment of Forehead/Glabellar Rhytide Complex With Onabotulinum Toxin A Versus Incobotulinum Toxin A Injection: A Split-face, Double-blinded, Randomized Control Trial

Active, not recruiting·NNorthwestern University·Phase 1·NCT02019004·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Onabotulinum Toxin A. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Onabotulinum Toxin A compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Onabotulinum Toxin A. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Walter Reed National Military Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: WWalter Reed National Military Medical Center

Onabotulinum Toxin A

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Trials by Indication[1]

Lung Cancer1 trial

Facial Wrinkles1 trial

Botulinum Toxin1 trial

Overactive Bladder1 trial

Migraine1 trial

Neuropathic Pain1 trial

Interstitial Cystitis1 trial

Conservative Management1 trial

Glabellar Lines1 trial

Wrinkles1 trial

References

Drug Info

Quick Facts

Related News